Notoriously hard to treat, pancreatic and colorectal cancers each have high recurrence rates in the years following treatment. A new 'off-the-shelf' vaccine with the catchy name ELI-002 2P offers fresh hope for individuals affected by these deadly diseases following promising outcomes in a recent clinical trial.

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive survival outcomes in patients with resected pancreatic and colorectal cancers, according to final results from the phase I AMPLIFY-201 trial.

The vaccine doesn't prevent cancer from happening in the first place, but an early-phase trial found it could reduce the odds of recurrence.